Stock POXEL POXEL
Add to a list
To use this feature you must be a member
Log inSign up

Financials Poxel

Equities

POXEL

FR0012432516

Biotechnology & Medical Research

Market Closed - Euronext Paris
Other stock markets
 11:35:26 2024-04-26 am EDT 		5-day change 1st Jan Change
0.673 EUR +1.97% Intraday chart for Poxel +2.91% +22.14%
Apr. 11 Poxel: CDC falls below the 10% threshold CF
Feb. 15 Poxel S.A. Reports Unaudited Revenue Results for the Fourth Quarter and Full Year Ended December 31, 2023 CI

Valuation

Fiscal Period: December 2017 2018 2019 2020 2021 2022
Capitalization 1 151.3 131.5 315.3 180.8 140.9 27.16
Enterprise Value (EV) 1 98.66 78.98 290.6 165.1 143.9 59.9
P/E ratio -6.79 x 9.6 x -12.3 x -5.48 x -5.92 x -0.87 x
Yield - - - - - -
Capitalization / Revenue 28.6 x 1.76 x 11.9 x 26.6 x 10.5 x 40.3 x
EV / Revenue 18.7 x 1.06 x 10.9 x 24.3 x 10.7 x 88.9 x
EV / EBITDA -4.51 x 6.27 x -12 x -5.55 x -6.44 x -2.75 x
EV / FCF 5.95 x -4.38 x -17.5 x -12.1 x -13.4 x -3.89 x
FCF Yield 16.8% -22.8% -5.71% -8.25% -7.46% -25.7%
Price to Book 7.85 x 2.36 x 8.12 x 6.73 x 17.2 x -1.55 x
Nbr of stocks (in thousands) 23,034 25,832 25,843 28,426 28,662 28,895
Reference price 2 6.570 5.090 12.20 6.360 4.916 0.9400
Announcement Date 4/27/18 4/9/19 4/21/20 3/26/21 5/18/22 5/3/23
1EUR in Million2EUR
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2017 2018 2019 2020 2021 2022
Net sales 1 5.29 74.6 26.56 6.806 13.4 0.674
EBITDA 1 -21.86 12.6 -24.25 -29.74 -22.36 -21.8
EBIT 1 -21.9 12.54 -24.67 -29.85 -22.46 -21.89
Operating Margin -414.02% 16.81% -92.9% -438.54% -167.67% -3,247.77%
Earnings before Tax (EBT) 1 -22.3 13.6 -25.74 -31.82 -23.76 -31.4
Net income 1 -22.3 13.52 -25.74 -31.86 -23.76 -31.4
Net margin -421.5% 18.13% -96.93% -468.09% -177.38% -4,658.46%
EPS 2 -0.9681 0.5300 -0.9926 -1.160 -0.8300 -1.080
Free Cash Flow 1 16.59 -18.04 -16.6 -13.62 -10.74 -15.41
FCF margin 313.53% -24.18% -62.5% -200.06% -80.17% -2,286.7%
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 4/27/18 4/9/19 4/21/20 3/26/21 5/18/22 5/3/23
1EUR in Million2EUR
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2019 S1 2019 S2 2020 S1 2020 S2 2021 S1 2021 S2 2022 S1 2022 S2 2023 S1
Net sales 1 23.2 9.1 6.4 0.327 13.27 0.123 0.083 0.591 0.955
EBITDA - - - - - - - - -
EBIT -5.864 -18.81 -12.19 -17.66 -6.851 -15.61 -12.18 -9.712 -
Operating Margin -25.28% -206.67% -190.48% -5,399.39% -51.61% -12,692.68% -14,672.29% -1,643.32% -
Earnings before Tax (EBT) -5.792 -19.95 -11.94 -19.88 -8.029 -15.73 -13.4 - -
Net income -5.792 -19.95 -12.06 -19.8 -8.029 -15.73 -13.4 -18 -
Net margin -24.97% -219.24% -188.44% -6,054.43% -60.49% -12,791.87% -16,145.78% -3,045.18% -
EPS -0.2200 -0.7700 -0.4500 -0.7100 -0.2800 -0.5500 -0.4600 -0.6200 -
Dividend per Share - - - - - - - - -
Announcement Date 8/26/19 3/26/20 9/15/20 3/26/21 9/23/21 3/22/22 9/21/22 3/23/23 -
1EUR in Million
Estimates

Balance Sheet Analysis

Fiscal Period: December 2017 2018 2019 2020 2021 2022
Net Debt 1 - - - - 3.01 32.7
Net Cash position 1 52.7 52.5 24.6 15.7 - -
Leverage (Debt/EBITDA) - - - - -0.1344 x -1.502 x
Free Cash Flow 1 16.6 -18 -16.6 -13.6 -10.7 -15.4
ROE (net income / shareholders' equity) -76% 36% -50.7% -96.5% -135% 626%
ROA (Net income/ Total Assets) -23.4% 9.1% -17.3% -27.2% -23.4% -30.5%
Assets 1 95.34 148.7 148.4 117.3 101.5 102.8
Book Value Per Share 2 0.8400 2.160 1.500 0.9400 0.2900 -0.6100
Cash Flow per Share 2 2.340 2.580 1.430 1.410 1.130 0.4300
Capex 1 0.04 0.21 0.07 0.24 0.03 0.01
Capex / Sales 0.67% 0.29% 0.27% 3.45% 0.21% 1.63%
Announcement Date 4/27/18 4/9/19 4/21/20 3/26/21 5/18/22 5/3/23
1EUR in Million2EUR
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
POXEL Stock Poxel
+22.14% 27.84M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-2.31% 103B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+0.56% 95.28B
ARGENX SE Stock argenx SE
+1.69% 22.15B
BIONTECH SE Stock BioNTech SE
-17.37% 21.02B
GENMAB A/S Stock Genmab A/S
-9.30% 18.15B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-41.01% 16.74B
BEIGENE, LTD. Stock BeiGene, Ltd.
-14.85% 16.05B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+3.21% 13.68B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+33.54% 12.17B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. POXEL Stock
  4. Financials Poxel